发明名称 |
Combinations of AKT inhibitor compounds and erlotinib, and methods of use |
摘要 |
The invention provides A combination of, a) a compound of Formula (I) or a pharmaceutically acceptable salt thereof; and b) erlotinib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.; |
申请公布号 |
US9150549(B2) |
申请公布日期 |
2015.10.06 |
申请号 |
US201214009313 |
申请日期 |
2012.03.30 |
申请人 |
Genentech, Inc. |
发明人 |
Nannini Michelle;Sampath Deepak |
分类号 |
A61K31/505;A61K31/517;C07D403/12;C07D239/70;A61K31/437;A61K31/496;A61K31/58;A61K31/282;A61K31/337;A61K31/4188;A61K31/4745;A61K31/513;A61K31/519;A61K31/704;A61K39/395;A61K39/00 |
主分类号 |
A61K31/505 |
代理机构 |
Viksnins Harris & Padys PLLP |
代理人 |
Viksnins Harris & Padys PLLP |
主权项 |
1. A combination of, a) a compound of Formula Ia: or a pharmaceutically acceptable salt thereof; and b) erlotinib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder. |
地址 |
South San Francisco CA US |